| scholarly article | Q13442814 |
| P50 | author | David Lockington | Q57065194 |
| Jennifer Hind | Q98726070 | ||
| P2093 | author name string | Elisabeth Macdonald | |
| P2860 | cites work | Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb | Q35854966 |
| Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. | Q39203016 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
| One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. | Q53836361 | ||
| A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. | Q54222666 | ||
| Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies | Q88073084 | ||
| P433 | issue | 4 | |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 685-686 | |
| P577 | publication date | 2018-11-29 | |
| P1433 | published in | Eye | Q10278937 |
| P1476 | title | Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease | |
| P478 | volume | 33 |
Search more.